If you read the transcript from the JP Morgan conference presentation last Thursday, it has a feeling of resignation about it (from the CEO). Sounding less enthusiastic about long-term viability of finding alternative sources of income beyond 2016, and the October 2013 trial date in the Roche lawsuit. Maybe that prompted a large holder to liquidate as the NPV of remaining cashflows (assuming a wind down of the company in 2016) may be less than the current stock price (which I think has been bid up because of the dividend yield). I think the value is somewhere between $6 and $7.
stocks go up and down. if it closes above 7.04 it still is on an uptrend. and if not, then it goes below and you can either sell or average down. you can either jump on a stock while it is shooting to the stars, and risk buying at the top, or buy something that has been beaten down and risk that it is not done being beaten. the risks go both ways. the dividend helps with this one.